SSA
PASG icon

Schonfeld Strategic Advisors’s Passage Bio PASG Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500
Closed -$13.8K – 2502
2022
Q4 		$13.8K Sell
500
-540
-52% -$13.6K ﹤0.01% 2344
2022
Q3 		$26K Sell
1,040
-1,539
-60% -$60.6K ﹤0.01% 2702
2022
Q2 		$122K Buy
2,579
+749
+41% +$35K ﹤0.01% 2078
2022
Q1 		$114K Buy
+1,830
New +$151K ﹤0.01% 2194
2020
Q4 		– Sell
-915
Closed -$240K – 1793
2020
Q3 		$240K Buy
+915
New +$315K ﹤0.01% 1162

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Schonfeld Strategic Advisors's PASG Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Passage Bio (PASG) in Q1 2023, closing a stake of 500 shares — an estimated $13.8K sold.

Schonfeld Strategic Advisors first reported a position in PASG in Q3 2020 and held it in 5 quarters. The position peaked at $240K in Q3 2020. 58 funds tracked by Wall St. Rank hold PASG as of Q1 2023.

  • Schonfeld Strategic Advisors reported no remaining Passage Bio position as of Q1 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 500 Passage Bio shares in Q1 2023, an estimated $13.8K.
  • Schonfeld Strategic Advisors first reported a position in Passage Bio in Q3 2020 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Passage Bio position peaked at $240K in Q3 2020.
  • 58 funds tracked by Wall St. Rank held Passage Bio as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.